8-K current report · filed Oct 8, 2026

Atrium Therapeutics, Inc. (RNA) 8-K Current Report: October 8, 2026

Item 8.01Item EX-99.1Item 1.01Item 3.02RNA overview

Short answer

Atrium Therapeutics, Inc. (RNA) filed an 8-K current report with the SEC on October 8, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities). $50 million gross PIPE financing, strengthening Atrium’s cash position before placement fees and offering expenses.

Atrium Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $50 million gross PIPE financing, strengthening Atrium’s cash position before placement fees and offering expenses
  • Issuance of 5,170,384 common shares plus pre-funded warrants for 1,134,930 shares, creating substantial dilution risk
  • Shares priced at $7.93, with warrants priced at $7.929 and a nominal $0.001 exercise price
  • Closing expected October 9, 2026, subject to customary conditions
  • Resale registration required within 50 days of closing, potentially increasing future trading supply and selling pressure

Item 3.02 · Unregistered Sales of Equity Securities

  • Unregistered financing under Securities Act Section 4(a)(2), avoiding public-offering registration requirements
  • Shares, pre-funded warrants and warrant shares issued or sold to investors
  • Offering terms, proceeds and potential dilution covered by Item 1.01, requiring review of that section for investor impact

Item 8.01 · Other Events

  • Planned offering targeting approximately $50 million gross proceeds before fees and expenses
  • Funding supports two lead candidates, research programs, working capital and general corporate purposes
  • Cash resources expected to fund operations through 2028, extending runway and reducing near-term financing risk
  • Post-offering shares outstanding expected at 22,276,027, indicating dilution for existing shareholders
  • Closing remains conditional, creating execution risk around proceeds and projected cash runway

Item EX-99.1 · Exhibit EX-99.1

  • $50 million private placement, priced at-the-market at $7.93 per share
  • Issuance of 5,170,384 shares plus pre-funded warrants for 1,134,930 shares, creating substantial dilution
  • Proceeds support lead candidates, research, working capital and corporate purposes
  • Cash, investments and financing expected to fund operations through 2028, extending near-term financing needs
  • Closing expected October 9, 2026, subject to customary conditions; resale registration required for investors' securities

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Atrium Therapeutics, Inc. 8-K filings

Get the next RNA 8-K as it lands

Follow RNA for push alerts, or ask the research agent what this filing means.